相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab
Lena-Alexandra Beume et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Spanish consensus on the use of natalizumab (Tysabri®)-2013
O. Fernandez et al.
NEUROLOGIA (2015)
Significant clinical worsening after natalizumab withdrawal: Predictive factors
A. Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
What to expect after natalizumab cessation in a real-life setting
S. Salhofer-Polanyi et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
Per Soelberg Sorensen et al.
JOURNAL OF NEUROLOGY (2014)
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
Antoine Gueguen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Fingolimod after natalizumab and the risk of short-term relapse
Vilija G. Jokubaitis et al.
NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)
Marinella Clerico et al.
JAMA NEUROLOGY (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
Joachim Havla et al.
JOURNAL OF NEUROLOGY (2013)
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?
Joachim Havla et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)
How does fingolimod (Gilenyal fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Franz Fazekas et al.
FRONTIERS IN NEUROLOGY (2013)
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Celia Oreja-Guevara et al.
BMC NEUROLOGY (2012)
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
L. Daelman et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
F. Rinaldi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
Sebastian Jander et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL
Valerie Rigau et al.
NEUROLOGY (2012)
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Augusto Miravalle et al.
ARCHIVES OF NEUROLOGY (2011)
Fingolimod for the treatment of relapsing multiple sclerosis
Douglas R. Jeffery et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Treatment with Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
Jaime Ramos-Cejudo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
Joachim Havla et al.
JOURNAL OF NEUROLOGY (2011)
Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
A. Kerbrat et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse
C. Papeix et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?
T. Lenhard et al.
NEUROLOGY (2010)
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
P. Kivisakk et al.
NEUROLOGY (2009)
GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
A. D. Goodman et al.
NEUROLOGY (2009)
Natalizumab: Targeting alpha(4)-integrins in multiple sclerosis
Britta Engelhardt et al.
NEURODEGENERATIVE DISEASES (2008)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
